Synbiotics in Infants With Cyanotic Congenital Heart Disease

NCT ID: NCT01810978

Last Updated: 2013-05-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infants with congenital heart disease have more frequent infections and exposures to antibiotics than healthy infants. The investigators hypothesized that synbiotics may reduce the rate of sepsis and necrotizing enterocolitis in infants with CHD

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infants with congenital heart disease have more frequent infections and exposures to antibiotics than healthy infants. Probiotics may prevent pathogen colonization in infants with CHD. Therefore, the investigators hypothesized that synbiotics may reduce the rate of sepsis and necrotizing enterocolitis in infants with CHD

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congenital Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bifidobacterium lactis plus inulin

Bifidobacterium lactis plus inulin

Group Type ACTIVE_COMPARATOR

Maltodextrin

Intervention Type DIETARY_SUPPLEMENT

same amount of maltodextrin per day will be given as placebo

maltodextrin

maltodextrin

Group Type PLACEBO_COMPARATOR

Bifidobacterium lactis plus inulin

Intervention Type DIETARY_SUPPLEMENT

5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bifidobacterium lactis plus inulin

5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin

same amount of maltodextrin per day will be given as placebo

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cyanotic congenital heart disease
* infants \>35 weeks of gestational age
* Born at or transferred to Sami Ulus CH

Exclusion Criteria

* Congenital anomalies of the intestinal tract
Minimum Eligible Age

1 Day

Maximum Eligible Age

3 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. Sami Ulus Children's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dilek Dilli

Assoc Prof

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Banu Aydın, MD

Role: PRINCIPAL_INVESTIGATOR

MD

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sami Ulus CH

Ankara, Ankara, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Ellis CL, Rutledge JC, Underwood MA. Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease. Gut Microbes. 2010 Nov-Dec;1(6):359-66. doi: 10.4161/gmic.1.6.14077.

Reference Type RESULT
PMID: 21468216 (View on PubMed)

Dilli D, Aydin B, Zenciroglu A, Ozyazici E, Beken S, Okumus N. Treatment outcomes of infants with cyanotic congenital heart disease treated with synbiotics. Pediatrics. 2013 Oct;132(4):e932-8. doi: 10.1542/peds.2013-1262. Epub 2013 Sep 16.

Reference Type DERIVED
PMID: 24043284 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ncbi.nlm.nih.gov/pubmed/21468216

http://www.ncbi.nlm.nih.gov/pubmed/21468216

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

128/01.10.2012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Synbiotics Cohort Study
NCT05046418 TERMINATED